Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Saphnelo | anifrolumab | Systemic lupus erythematosus | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vraylar | cariprazine | Bipolar Disorder | Do not reimburse | Complete | ||
| Vabysmo | faricimab | Macular degeneration, age-related | Reimburse with clinical criteria and/or conditions | Complete | ||
| Doptelet | avatrombopag | Chronic immune thrombocytopenia (ITP) | Active | |||
| Keytruda | pembrolizumab | Triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Opdivo | nivolumab | Urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Orladeyo | berotralstat | hereditary angioedema (HAE) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Qulipta | atogepant | Migraine, prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zepzelca | lurbinectedin | metastatic small cell lung cancer (SCLC) | Do not reimburse | Complete | ||
| Tecentriq | atezolizumab | Non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024